Allergan acquires clinical stage biopharma company Anterios

Allergan plc, a leading global pharmaceutical company, announced that it has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products.

Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential development and commercialisation milestone payments related to NDS, Anterios’ proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections.

In addition to NDS, Allergan has acquired global rights to ANT-1207, an investigational topical formulation botulinum toxin type A in development for the potential treatment of hyperhidrosis (excessive sweating), acne, and crow’s feet lines.

The NDS platform technology and ANT-1207 add to Allergan’s strong neurotoxin pipeline, with BOTOX Cosmetic (onabotulinumtoxinA) currently in development for treating forehead lines, masseter hypertrophy and platysma bands and BOTOX Therapeutic in development for osteoarthritis and depression.